Harmony Biosciences Holdings, Inc. (HRMY) Comparison with companies in other sectors?

Harmony Biosciences Holdings, Inc. has a share price of 57.42M. You can analyze Harmony Biosciences Holdings, Inc. (HRMY) competitors across different market sectors through stock heatmaps.

What are HRMY's NET and operating margins?

Harmony Biosciences Holdings, Inc. (HRMY) operating margin is around 0.26, and net profit margin is approximately 0.21 as of the latest reports.

In what way does HRMY's earnings per share (EPS) trend reflect its financial momentum?

Harmony Biosciences Holdings, Inc. (HRMY) EPS is 2.62 (If EPS value is positive, then “signals consistent profit growth” if Negative then “signals consistent loss”). This metric is also critical in assessing valuation metrics like the P/E ratio for Harmony Biosciences Holdings, Inc. is 14.32, and the company’s ability to reinvest or distribute profits.

What does a high ROE mean for Harmony Biosciences Holdings, Inc.?

A high ROE suggests efficient use of shareholder equity to generate profit. It often signals strong management and profitability.

How do I know if AAPL is overvalued or undervalued?

Check valuation ratios for Harmony Biosciences Holdings, Inc. like P/E which is 13.69, P/B which is 2.90, and PEG which is 3.19. Compare them with sector averages to evaluate if the stock is priced fairly.

Harmony Biosciences Holdings, Inc.

HRMY•NASDAQ

Healthcare

Biotechnology

$37.52

$0.81(2.21%)

Fundamental Analysis of Harmony Biosciences Holdings, Inc. (HRMY)

Comprehensive financial metrics and ratios analysis

EPS (TTM)

$2.62

P/E Ratio

14.32

ROE

0.24%

Net Margin

0.21%

Key Financial Metrices

Valuation Metrics

4 metrics

Market CapTotal market value of outstanding shares

$2.15B

Shares OutstandingTotal number of shares issued

$57.42M

Book Value/ShareNet worth per share

$12.57

Revenue/ShareAnnual revenue per share

$13.00

Profitability Metrics

6 metrics

EPS (TTM)Earnings per share trailing twelve months

$2.62

Net MarginNet income as percentage of revenue

20.50%

Operating MarginOperating income as percentage of revenue

26.18%

ROEReturn on shareholders' equity

24.29%

ROAReturn on total assets

14.47%

ROCEReturn on capital employed

22.15%

Cash Flow Metrics

3 metrics

Free Cash Flow/ShareCash generated per share after capex

$3.86

Cash/ShareCash and equivalents per share

$8.53

FCF YieldFree cash flow as percentage of market cap

10.37%

Dividend Metrics

2 metrics

Dividend/ShareAnnual dividend payment per share

Dividend YieldAnnual dividend as percentage of stock price

Financial Ratios Analysis data is not available for HRMYFinancial Ratios Analysis details for HRMY are currently unavailable. We're actively monitoring for updates and will publish them as soon as they’re released. Please check back again shortly.

Sector Benchmarking data is not available for HRMYSector Benchmarking details for HRMY are currently unavailable. We're actively monitoring for updates and will publish them as soon as they’re released. Please check back again shortly.

Understanding Fundamental Analysis for Harmony Biosciences Holdings, Inc. Investment Decisions

What is Fundamental Analysis?

Fundamental analysis is a method used to assess the intrinsic value of Harmony Biosciences Holdings, Inc.. Using financial reports, management structure, competitive position, and market environment, investors can determine whether the stock is undervalued or overvalued. This analysis helps investors like you make more informed investment decisions, taking into account Harmony Biosciences Holdings, Inc.'s unique business strengths and challenges.

Key Financial Metrics for Harmony Biosciences Holdings, Inc.

For Harmony Biosciences Holdings, Inc., essential financial indicators include EPS 2.62, PE 14.32, and ROE 0.24. These key ratios reveal insights into Harmony Biosciences Holdings, Inc.'s profitability, valuation, and operational health. Understanding these metrics enables you to compare Harmony Biosciences Holdings, Inc. with its industry peers and decide whether it presents a viable investment opportunity.

Profitability and Operational Efficiency of Harmony Biosciences Holdings, Inc.

Metrics like Net Margin 20.50% and ROA 14.47% shed light on how well Harmony Biosciences Holdings, Inc. is generating profits. A high profitability ratio often indicates strong management and a solid business model, which are essential for long-term growth. These metrics are crucial in assessing whether Harmony Biosciences Holdings, Inc. can sustain its operations and continue growing in the future.

Valuation and Market Position of Harmony Biosciences Holdings, Inc.

Using ratios such as P/B Ratio 2.90 and PEG Ratio 3.19, investors can assess whether Harmony Biosciences Holdings, Inc. is appropriately valued based on its financials and growth potential. These figures, combined with Harmony Biosciences Holdings, Inc.'s market capitalization, give insight into its competitive positioning and investor expectations, helping you make informed decisions on pricing and value.

Financial Health and Risk Assessment for Harmony Biosciences Holdings, Inc.

Financial health indicators, such as Debt/Equity Ratio 0.02 and Cash Flow $3.86, provide a snapshot of Harmony Biosciences Holdings, Inc.'s ability to meet financial obligations and handle economic setbacks. A company with a strong balance sheet and solid cash flow, like Harmony Biosciences Holdings, Inc., is more likely to weather financial storms, making it a safer investment.

Long-Term Investment Strategy for Harmony Biosciences Holdings, Inc.

Investing in Harmony Biosciences Holdings, Inc. based on fundamental analysis emphasizes long-term business growth rather than short-term market trends. Investors looking at Harmony Biosciences Holdings, Inc. focus on its solid financial performance, industry standing, and competitive advantages, all of which suggest sustainable growth and the potential for steady returns over time.

Fundamental Analysis FAQ

;